Fig. 1: Effect of DSGOST, TJ-38, and cisplatin in gastric cancer.

a, b Cell viability of DSGOST and TJ-38 in gastric cancer cells measured using WST-1 on 96-well plates, and DSGOST and TJ-38 were treated in a dose-dependent manner (100, 300, and 500 μg/mL; 24 h). c Cell viability of DSGOST in gastric cancer cells measured using WST-1 on 96-well plates, and DSGOST was treated in a time-dependent manner (500 μg/mL; 8, 24, and 48 h) d Cell viability of DSGOST (500 μg/mL, 24 h) and TJ-38 (500 μg/mL, 24 h) using WST-1 in gastric cancer cells. e Cell viability of DSGOST (500 μg/mL, 24 h) or TJ-38 (500 μg/mL, 24 h) in combination with cisplatin (5 µM, 24 h) measured in gastric cancer cells using WST-1. Cell viability of DMSO-treated control cells was set at 100%; *p < 0.05